Encompass Health Corp Files 8-K for Regulation FD Disclosure

TL;DR

Encompass Health dropped an 8-K today, likely a material update under Reg FD.

AI Summary

Encompass Health Corporation announced on May 29, 2024, that it is providing a Regulation FD Disclosure. The filing does not contain specific details about the nature of the disclosure, dollar amounts, or other specific events, but it indicates a material event requiring immediate public notification.

Why It Matters

This filing signals a potentially significant event or update from Encompass Health that is being disclosed to the public under Regulation FD, which requires fair disclosure of material information.

Risk Assessment

Risk Level: medium — The filing of an 8-K for a Regulation FD disclosure often indicates material information is being released, which could impact the company's stock price.

Key Players & Entities

• Encompass Health Corporation (company) — Registrant
• Regulation FD (regulation) — Disclosure requirement

FAQ

Key Financial Figures

• $0.01 — ich registered Common Stock, par value $0.01 per share EHC New York Stock Exchange
• $5,250 million — 2024 ranges: Net operating revenue of $5,250 million to $5,325 million; Adjusted EBITDA of
• $5,325 million — operating revenue of $5,250 million to $5,325 million; Adjusted EBITDA of $1,030 million to
• $1,030 million — to $5,325 million; Adjusted EBITDA of $1,030 million to $1,065 million; and Adjusted earnin
• $1,065 million — ; Adjusted EBITDA of $1,030 million to $1,065 million; and Adjusted earnings per share from
• $3.86 — ons attributable to Encompass Health of $3.86 to $4.11. The information contained he
• $4.11 — butable to Encompass Health of $3.86 to $4.11. The information contained herein is b
• $145 million — debt discounts and fees - approximately $145 million Amortization of debt-related items - a
• $10 million — n of debt-related items - approximately $10 million Forward-Looking Statements Statement

Filing Documents

• ehc-20240529.htm (8-K) — 33KB
• 0000785161-24-000034.txt ( ) — 157KB
• ehc-20240529.xsd (EX-101.SCH) — 2KB
• ehc-20240529_lab.xml (EX-101.LAB) — 21KB
• ehc-20240529_pre.xml (EX-101.PRE) — 12KB
• ehc-20240529_htm.xml (XML) — 3KB

01. Regulation FD Disclosure

ITEM 7.01. Regulation FD Disclosure. Encompass Health Corporation (the "Company" or "Encompass Health") will participate in the Leerink Partners Healthcare Crossroads Conference in Austin, Texas, being held May 28-30, 2024. Encompass Health's President and Chief Executive Officer Mark Tarr and Executive Vice President and Chief Financial Officer Doug Coltharp will participate in a fireside chat on Thursday, May 30, 2024, from 9:00-9:30 a.m. ET. The fireside chat will be webcast live and will be available at http://investor.encompasshealth.com by clicking on an available link. The Company reiterates as of the date hereof its guidance previously reported in the Current Report on Form 8-K, dated April 24, 2024, and during the Company's earnings conference call held on April 25, 2024. Accordingly, the Company continues to expect the following full-year 2024 ranges: Net operating revenue of $5,250 million to $5,325 million; Adjusted EBITDA of $1,030 million to $1,065 million; and Adjusted earnings per share from continuing operations attributable to Encompass Health of $3.86 to $4.11. The information contained herein is being furnished pursuant to Item 7.01 of Form 8-K, "Regulation FD Disclosure." This information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The furnishing of this information will not be deemed an admission as to the materiality of any information contained herein. Note Regarding Presentation of Non-GAAP Financial Measures Excluding net operating revenues, the Company does not provide guidance on a GAAP basis because it is unable to predict, with reasonable certainty, the future impact of items that are deemed to be outside the control of the Company or otherwise not indicative o

Forward-Looking Statements

Forward-Looking Statements

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. ENCOMPASS HEALTH CORPORATION By: / S / D OUGLAS E. C OLTHARP Name: Douglas E. Coltharp Title: Executive Vice President and Chief Financial Officer Dated: May 29, 2024

View Full Filing

View this 8-K filing on SEC EDGAR